Application
Figure 1:Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)Application
Figure 2:Western blot analysis using BCL9L mAb against human BCL9L (AA: 606-751) recombinant protein. (Expected MW is 41.9 kDa)Application
Figure 3:Western blot analysis using BCL9L mAb against HEK293 (1) and BCL9L (AA: 606-751)-hIgGFc transfected HEK293 (2) cell lysate.Application
Figure 4:Immunohistochemical analysis of paraffin-embedded cervical cancer tissues using BCL9L mouse mAb with DAB staining.| Product Name | BCL9L |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | BCL9-2; DLNB11 |
| Immunogen | Purified recombinant fragment of human BCL9L (AA: 606-751) expressed in E. Coli. |
| Clonality | Monoclonal |
|---|---|
| Host Species | Unknow |
| Tested Applications | WBIHCICC/IF |
| WB:1:250~1:1000 IHC:1:20~1:100 ICC/IF:1:100~1:200 Notes:Optimal dilutions/concentrations should be determined by the researcher. |
|
| Species Reactivity | Human |
| Alternative Names | BCL9-2 DLNB11 |
|---|---|
| Molecular Weight(MW) | 157kDa |
| Entrez Gene | 283149 |
|---|
Application
Figure 1:Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)
Application
Figure 2:Western blot analysis using BCL9L mAb against human BCL9L (AA: 606-751) recombinant protein. (Expected MW is 41.9 kDa)
Application
Figure 3:Western blot analysis using BCL9L mAb against HEK293 (1) and BCL9L (AA: 606-751)-hIgGFc transfected HEK293 (2) cell lysate.
Application
Figure 4:Immunohistochemical analysis of paraffin-embedded cervical cancer tissues using BCL9L mouse mAb with DAB staining.| Application Notes | WB:1:250~1:1000 IHC:1:20~1:100 ICC/IF:1:100~1:200 Notes:Optimal dilutions/concentrations should be determined by the researcher. |
|---|
| Form | Purified antibody in PBS with 0.05% sodium azide |
|---|---|
| Storage Instructions | 4℃; -20℃ for long term storage |
